Research programme: androgen receptor antagonists - Janssen Research & Development

Drug Profile

Research programme: androgen receptor antagonists - Janssen Research & Development

Alternative Names: SARD programme - Aragon Pharmaceuticals

Latest Information Update: 28 Aug 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of California System
  • Developer Janssen Research & Development
  • Class Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Prostate cancer

Most Recent Events

  • 19 Aug 2013 Aragon Pharmaceuticals has been acquired and merged into Johnson & Johnson
  • 01 Oct 2012 Early research in Prostate cancer (hormone refractory) is ongoing in USA
  • 22 Apr 2010 Early research in Prostate cancer (hormone refractory) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top